Shares of Biogen Inc. BIIB shed 1.44% to $115.29 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to 5,275.70 and Dow ...

Jefferies analyst Michael Yee maintained a Hold rating on Biogen (BIIB – Research Report) today and set a price target of $130.00. The ...

Shares of Biogen Inc. BIIB slipped 5.90% to $113.38 Thursday, on what proved to be an all-around rough trading session for ...

Organon acquired regulatory and commercial rights in the United States for TOFIDENCE ™, a biosimilar to ACTEMRA ®, for intravenous infusion from Biogen. TOFIDENCE, the first approved ...

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA ...

U.S. President Donald Trump signs an executive order about tariffs increase in the Oval Office of the White House in Washington, D.C. Kevin Lamarque/Reuters President Donald Trump has announced ...

Biogen's new management is diversifying its product portfolio and optimizing costs, but faces significant risks from market share loss and generic competition. The fair valuation of Biogen shares ...

These aren’t fun times for billionaires, even though their number keeps proliferating along with their numbers — there are now at least 17 documented “super billionaires” with assets of ...

Biogen briefly moved its headquarters out to Weston, a town 30 minutes from Kendall Square, in 2010 before quickly announcing it would move back to Cambridge a year later.

Download the free “New Cannabis Ventures” app on the iOS App Store or Google Play and get real-time push notifications straight to your phone on the latest breaking news and exclusives published.

LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...